Cargando…

Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer

SIMPLE SUMMARY: Prostate cancer is a heterogeneous disease and a major cause of cancer deaths worldwide. The most widely used prostate cancer biomarker, prostate-specific antigen, lacks sensitivity and specificity in the diagnosis of malignant disease. Hence, novel tissue-based biomarkers have emerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eickelschulte, Samaneh, Riediger, Anja Lisa, Angeles, Arlou Kristina, Janke, Florian, Duensing, Stefan, Sültmann, Holger, Görtz, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777028/ https://www.ncbi.nlm.nih.gov/pubmed/36551580 http://dx.doi.org/10.3390/cancers14246094

Ejemplares similares

Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Genome-Based Classification and Therapy of Prostate Cancer
por: Angeles, Arlou Kristina, et al.
Publicado: (2018)

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
por: Angeles, Arlou Kristina, et al.
Publicado: (2023)

An artificial intelligence-based chatbot for prostate cancer education: Design and patient evaluation study
por: Görtz, Magdalena, et al.
Publicado: (2023)

Impact of Surgeon’s Experience in Rigid versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores
por: Görtz, Magdalena, et al.
Publicado: (2022)

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
por: Dietz, Steffen, et al.
Publicado: (2017)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
por: Schindler, Hannah, et al.
Publicado: (2022)

Biomarkers for prostate cancer detection and risk stratification
por: Farha, Mark W., et al.
Publicado: (2022)

Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer
por: Murphy, Keefe, et al.
Publicado: (2018)

TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells
por: Ratz, Leonie, et al.
Publicado: (2017)

miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells
por: Bauer, Simone, et al.
Publicado: (2021)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
por: Riediger, Anja Lisa, et al.
Publicado: (2016)

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Biomarkers of Aggressive Prostate Cancer at Diagnosis
por: Boehm, Brock E., et al.
Publicado: (2023)

Blood-Based Biomarkers of Aggressive Prostate Cancer
por: Liong, Men Long, et al.
Publicado: (2012)

Evaluation of protein biomarkers of prostate cancer aggressiveness
por: Rizzardi, Anthony E, et al.
Publicado: (2014)

Retzius-sparing robot-assisted laparoscopic radical prostatectomy: functional and early oncologic results in aggressive and locally advanced prostate cancer
por: Nyarangi-Dix, Joanne Nyaboe, et al.
Publicado: (2019)

Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification
por: Gennaro, Kyle H., et al.
Publicado: (2018)

Assessment of the Utility of Gene Positioning Biomarkers in the Stratification of Prostate Cancers
por: Meaburn, Karen J., et al.
Publicado: (2019)

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL
por: Dieffenbacher, Svenja, et al.
Publicado: (2018)

Linking cellular metabolism and metabolomics to risk-stratification of prostate cancer clinical aggressiveness and potential therapeutic pathways
por: Eidelman, Eric, et al.
Publicado: (2018)

Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma
por: Schneider, Felix, et al.
Publicado: (2023)

Novel approaches for the identification of biomarkers of aggressive prostate cancer
por: Kim, Yunee, et al.
Publicado: (2013)

AKT/AMPK-mediated phosphorylation of TBC1D4 disrupts the interaction with insulin-regulated aminopeptidase
por: Eickelschulte, Samaneh, et al.
Publicado: (2021)

Effects of a smartphone app-augmented treatment for children with oppositional defiant disorder / conduct disorder and peer-related aggressive behavior – a pilot study
por: Görtz-Dorten, Anja, et al.
Publicado: (2022)

A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer
por: Song, Jin, et al.
Publicado: (2021)

Serum microRNAs as non-invasive biomarkers for cancer
por: Brase, Jan C, et al.
Publicado: (2010)

Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression
por: Pickl, Julia M.A., et al.
Publicado: (2016)

Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness
por: Giskeødegård, Guro F., et al.
Publicado: (2013)

The Role of Adhesion Molecules as Biomarkers for the Aggressive Prostate Cancer Phenotype
por: Morgan, Claire, et al.
Publicado: (2013)

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer
por: Martínez-González, Luis Javier, et al.
Publicado: (2021)

The potential of miR-153 as aggressive prostate cancer biomarker
por: Gilyazova, Irina, et al.
Publicado: (2022)

Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification
por: Guo, Jinan, et al.
Publicado: (2020)

Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer
por: Basourakos, Spyridon P., et al.
Publicado: (2021)

ARHGEF38 as a novel biomarker to predict aggressive prostate cancer
por: Liu, Kun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_07u5inv431vneos760en6pgmdl